{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:10:47Z","timestamp":1773249047496,"version":"3.50.1"},"reference-count":37,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRCEP"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To determine the efficacy of the first triple CFTR protein modulators in children\nand adolescents with cystic fibrosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Systematic review and meta-analysis were conducted, following PRISMA guidelines. The\nfollowing databases were searched extensively: PubMed\/Medline, Clinical trials.gov, Google Scholar,\nScopus, Embase, and Europe PMC using the keywords: \u201cIvacaftor\u201d, \u201cElexacaftor\u201d, \u201cTezacaftor\u201d,\nVX_661\u201d, VX_770\u201d, \u201cVX_445\u201d, \u201ccystic fibrosis\u201d. A total of ten randomized clinical trials were included\nin our analysis. Primary outcomes included: Absolute change in predicted FEV1 from baseline,\nAbsolute change in sweat chloride test from baseline, Absolute change in BMI from baseline, Absolute\nchange in CF-QR from baseline, and Adverse Events.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Among primary findings, significant absolute change in predictive FEV1 from baseline\nthrough 4 weeks favoured the triple CFTR protein modulators. (MD = 11.80, 95% CI = 8.47_15.12, p\nvalue = &lt;0.00001); as well as CF_QR score (MD = 0.00, 95% CI = -2.50_2.50, p value = 1.00), and\nBMI kg\/m\u00b2 change (MD = 16.90, 95% CI = 12.73_21.06, p value = &lt;0.00001). No significant change\nwas noted for CFTR channels activity in the treatment group when compared to placebo or\nVX_770\/VX_661 (MD = -12.57, 95% CI = -94.46_69.32, p value = 0.76).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>In children aged \u2265 6 y old and adolescents with F508del_CFTR mutation, Elexacaftor-\nTezacaftor-Ivacaftor tend to be more effective than first-generation therapy, demonstrating promising\nresults by exhibiting significant improvement in lung function, body weight, and respiratory-related\nquality of life.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/2772432818666230201094115","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T04:10:21Z","timestamp":1675311021000},"page":"93-110","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cystic Fibrosis Transmembrane Conductance Regulator Protein Modulators\nin Children and Adolescents with Different CF Genotypes - Systematic\nReview and Meta-Analysis"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-2830","authenticated-orcid":true,"given":"Alaa Hassan","family":"Yousif Hamdan","sequence":"first","affiliation":[{"name":"Larkin Community Hospital Division of Clinical and Transitional Research, South Miami, Florida, USA"},{"name":"Department\nof Paediatrics, Sudan Medical Specialization Board, Khartoum, Sudan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiza","family":"Zakaria","sequence":"additional","affiliation":[{"name":"Dow Medical College, Dow University of\nHealth Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2088-6243","authenticated-orcid":true,"given":"Maria Kezia","family":"Lourdes Pormento","sequence":"additional","affiliation":[{"name":"Ateneo School of Medicine and Public Health, Pasig, Philippines"},{"name":"Department\nof Internal Medicine, Larkin Community Hospital, South Miami, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4365-7427","authenticated-orcid":true,"given":"Odunayo Susan","family":"Lawal","sequence":"additional","affiliation":[{"name":"Clinical Translational Sciences, University\nof Arizona, Tucson, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8193-2760","authenticated-orcid":true,"given":"Adaugo","family":"Opiegbe","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Benin, Benin City, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6136-2724","authenticated-orcid":true,"given":"Samina","family":"Zahid","sequence":"additional","affiliation":[{"name":"Department\nof Internal Medicine, Larkin Community Hospital, South Miami, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6683-9357","authenticated-orcid":true,"given":"Prathima","family":"Guntipalli","sequence":"additional","affiliation":[{"name":"Department\nof Internal Medicine, Larkin Community Hospital, South Miami, Florida"},{"name":"Department -\nHealth Care Administration, Texas Woman\u2019s University, Dallas, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2077-7338","authenticated-orcid":true,"given":"Ujala","family":"Nasr","sequence":"additional","affiliation":[{"name":"Dow Medical College, Dow University of\nHealth Sciences, Karachi, Pakistan"},{"name":"Department of Internal Medicine, Nazareth\nHospital, Philadelphia, PA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Asad","family":"Hasan Rizvi","sequence":"additional","affiliation":[{"name":"Dow Medical College, Dow University of\nHealth Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/01.JAA.0000515540.36581.92","volume":"30","author":"Brown S.D.","year":"2017","unstructured":"Brown S.D.; White R.; Tobin P.; Keep them breathing. JAAPA 2017,30(5),23-27","journal-title":"JAAPA"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"Elborn J.S.","year":"2016","unstructured":"Elborn J.S.; Cystic fibrosis. Lancet 2016,388(10059),2519-2531","journal-title":"Lancet"},{"key":"ref=3","author":"Yu E.","year":"2021","unstructured":"Yu E.; Sharma S.;  Cystic Fibrosis 2021","journal-title":"Cystic Fibrosis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1165\/rcmb.2014-0250OC","volume":"52","author":"Keiser N.W.","year":"2015","unstructured":"Keiser N.W.; Birket S.E.; Evans I.A.; Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungs. Am J Respir Cell Mol Biol 2015,52(6),683-694","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12890-021-01528-0","volume":"21","author":"Mathew H.R.","year":"2021","unstructured":"Mathew H.R.; Choi M.Y.; Parkins M.D.; Fritzler M.J.; Systematic review: Cystic fibrosis in the SARS-CoV-2\/COVID-19 pandemic. BMC Pulm Med 2021,21(1),173","journal-title":"BMC Pulm Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/genes10030235","volume":"10","author":"Swahn H.","year":"2019","unstructured":"Swahn H.; Harris A.; Cell-selective regulation of CFTR gene expression: Relevance to gene editing therapeutics. Genes 2019,10(3),235","journal-title":"Genes"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s004310051317","volume":"159","author":"Dawson K.P.","year":"2000","unstructured":"Dawson K.P.; Frossard P.M.; The geographic distribution of cystic fibrosis mutations gives clues about population origins. Eur J Pediatr 2000,159(7),496-499","journal-title":"Eur J Pediatr"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","volume":"10","author":"Lopes-Pacheco M.","year":"2020","unstructured":"Lopes-Pacheco M.; CFTR modulators: The changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol 2020,10,1662","journal-title":"Front Pharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jcf.2013.12.003","volume":"13","author":"De Boeck K.","year":"2014","unstructured":"De Boeck K.; Zolin A.; Cuppens H.; Olesen H.V.; Viviani L.; The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. J Cyst Fibros 2014,13(4),403-409","journal-title":"J Cyst Fibros"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"Heijerman H.G.M.","year":"2019","unstructured":"Heijerman H.G.M.; McKone E.F.; Downey D.G.; Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial. Lancet 2019,394(10212),1940-1948","journal-title":"Lancet"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00018-016-2387-7","volume":"74","author":"Farinha C.M.","year":"2017","unstructured":"Farinha C.M.; Canato S.; From the endoplasmic reticulum to the plasma membrane: Mechanisms of CFTR folding and trafficking. Cell Mol Life Sci 2017,74(1),39-55","journal-title":"Cell Mol Life Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5339\/qmj.2021.24","volume":"2021","year":"2021","unstructured":"AlNaimi A, Habra B, Janahi I. First report of the cystic fibrosis transmembrane conductance regulator mutation c.1521_1523delCTT (p. Phe508del) in two Qatari patients with cystic fibrosis. Qatar Med J AbdulWahab A2021,2021(2),24","journal-title":"Qatar Med J"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1113\/jphysiol.2010.202861","volume":"589","author":"Jih K.Y.","year":"2011","unstructured":"Jih K.Y.; Li M.; Hwang T.C.; Bompadre S.G.; The most common cystic fibrosis-associated mutation destabilizes the dimeric state of the nucleotide-binding domains of CFTR. J Physiol 2011,589(11),2719-2731","journal-title":"J Physiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"5882","DOI":"10.3390\/ijms21165882","volume":"21","author":"Gramegna A.","year":"2020","unstructured":"Gramegna A.; Contarini M.; Aliberti S.; Casciaro R.; Blasi F.; Castellani C.; From ivacaftor to triple combination: A systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis. Int J Mol Sci 2020,21(16),5882","journal-title":"Int J Mol Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"Keating D.","year":"2018","unstructured":"Keating D.; Marigowda G.; Burr L.; VX-445\u2013Tezacaftor\u2013ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med 2018,379(17),1612-1620","journal-title":"N Engl J Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","volume":"377","author":"Rowe S.M.","year":"2017","unstructured":"Rowe S.M.; Daines C.; Ringshausen F.C.; Tezacaftor\u2013ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med 2017,377(21),2024-2035","journal-title":"N Engl J Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","volume":"187","author":"Davies J.C.","year":"2013","unstructured":"Davies J.C.; Wainwright C.E.; Canny G.J.; Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013,187(11),1219-1225","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S2213-2600(15)00201-5","volume":"3","author":"Moss R.B.","year":"2015","unstructured":"Moss R.B.; Flume P.A.; Elborn J.S.; Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: A double-blind, randomised controlled trial. Lancet Respir Med 2015,3(7),524-533","journal-title":"Lancet Respir Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"Middleton PG","year":"2019","unstructured":"Middleton PG; Mall MA; D\u0159ev\u00ednek P; Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 2019,381(19),1809-1819","journal-title":"N Engl J Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","volume":"365","author":"Ramsey B.W.","year":"2011","unstructured":"Ramsey B.W.; Davies J.; McElvaney N.G.; A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011,365(18),1663-1672","journal-title":"N Engl J Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2002774","DOI":"10.1183\/13993003.02774-2020","volume":"57","author":"Laselva O.","year":"2021","unstructured":"Laselva O.; Bartlett C.; Gunawardena T.N.A.; Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator. Eur Respir J 2021,57(6),2002774","journal-title":"Eur Respir J"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e139983","DOI":"10.1172\/jci.insight.139983","volume":"5","author":"Veit G.","year":"2020","unstructured":"Veit G.; Roldan A.; Hancock M.A.; Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination. JCI Insight 2020,5(18),e139983","journal-title":"JCI Insight"},{"key":"ref=22a","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"Luo D.","year":"2018","unstructured":"Luo D.; Wan X.; Liu J.; Tong T.; Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res 2018,27(6),1785-1805","journal-title":"Stat Methods Med Res"},{"key":"ref=22b","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"Wan X.","year":"2014","unstructured":"Wan X.; Wang W.; Liu J.; Tong T.; Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 2014,14,1-3","journal-title":"BMC Med Res Methodol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1056\/NEJMra043184","volume":"352","author":"Rowe S.M.","year":"2005","unstructured":"Rowe S.M.; Miller S.; Sorscher E.J.; Cystic Fibrosis. N Engl J Med 2005,352(19),1992-2001","journal-title":"N Engl J Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1378\/chest.11-2672","volume":"142","author":"Flume P.A.","year":"2012","unstructured":"Flume P.A.; Liou T.G.; Borowitz D.S.; Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012,142(3),718-724","journal-title":"Chest"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"00082","DOI":"10.1183\/23120541.00082-2019","volume":"5","author":"Taylor-Cousar J.L.","year":"2019","unstructured":"Taylor-Cousar J.L.; Mall M.A.; Ramsey B.W.; Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Res 2019,5(2),00082-02019","journal-title":"ERJ Open Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jcf.2020.04.015","volume":"19","author":"Munck A.","year":"2020","unstructured":"Munck A.; Kerem E.; Ellemunter H.; Tezacaftor\/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations. J Cyst Fibros 2020,19(6),962-968","journal-title":"J Cyst Fibros"},{"key":"ref=27","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.LSC-2021.104","volume":"7","author":"Rink S.","year":"2021","unstructured":"Rink S.; Jani\u0107 M, Lunder M, \u0160abovi\u010d M, Salobir B. Effect of elexacaftor-tezacaftor-ivacaftor on pulmonary and endothelial function in a patient with advanced cystic fibrosis. ERJ Open Res 2021,7(S6)","journal-title":"ERJ Open Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jcf.2021.05.009","volume":"20","author":"Bermingham B,A R, G R","year":"2021","unstructured":"Bermingham B,A R, G R; Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease. J Cyst Fibros 2021,20(5),768-771","journal-title":"J Cyst Fibros"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1513\/AnnalsATS.201609-689OC","volume":"14","author":"Rowe S.M.","year":"2017","unstructured":"Rowe S.M.; McColley S.A.; Rietschel E.; Lumacaftor\/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR. Ann Am Thorac Soc 2017,14(2),213-219","journal-title":"Ann Am Thorac Soc"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1002\/ppul.24157","volume":"53","author":"Clancy J.P.","year":"2018","unstructured":"Clancy J.P.; Rapid therapeutic advances in CFTR modulator science. Pediatr Pulmonol 2018,53(S3),S4-S11","journal-title":"Pediatr Pulmonol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1164\/rccm.201704-0717OC","volume":"197","author":"Donaldson S.H.","year":"2018","unstructured":"Donaldson S.H.; Tezacaftor\/ivacaftor in subjects with cystic fibrosis and F508del\/F508del-CFTR or F508del\/G551D-CFTR. Am J Respir Crit Care Med 2018,197(2),214-224","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","volume":"8","author":"Bell S.C.","year":"2020","unstructured":"Bell S.C.; Mall M.A.; Gutierrez H.; The future of cystic fibrosis care: A global perspective. Lancet Respir Med 2020,8(1),65-124","journal-title":"Lancet Respir Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jcf.2020.06.001","volume":"20","author":"Schwarz C.","year":"2021","unstructured":"Schwarz C.; Sutharsan S.; Epaud R.; Tezacaftor\/ivacaftor in people with cystic fibrosis who stopped lumacaftor\/ivacaftor due to respiratory adverse events. J Cyst Fibros 2021,20(2),228-233","journal-title":"J Cyst Fibros"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","volume":"204","author":"Burgel P.R.","year":"2021","unstructured":"Burgel P.R.; Durieu I.; Chiron R.; Ramel S.; Danner-Boucher I.; Prevotat A.; Rapid improvement after starting elexacaftor\u2013tezacaftor\u2013ivacaftor in patients with cystic fibrosis and advanced pulmonary disease. Am J Respir Crit Care Med 2021,204(1),64-73","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jcf.2020.07.023","volume":"20","author":"Davies J.C.","year":"2021","unstructured":"Davies J.C.; Sermet-Gaudelus I.; Naehrlich L.; Harris R.S.; Campbell D.; Ahluwalia N.; A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation. J Cyst Fibros 2021,20(1),68-77","journal-title":"J Cyst Fibros"}],"container-title":["Current Reviews in Clinical and Experimental Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2772432818666230201094115","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/213322\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2772432818666230201094115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T12:29:41Z","timestamp":1699619381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/213322\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2772432818666230201094115","relation":{},"ISSN":["2772-4328"],"issn-type":[{"value":"2772-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}